NCT07242534RecruitingPhase 4
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 19 Jan 2026
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Fundacion Dexeus
- Diseases
- Obesity
- NCT number
- NCT07242534
- EU CT number
- 2025-522525-34-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 62
- From 19 Jan 2026 to the primary completion date, 28 Feb 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of GLP-1 Ras within the past year
- Use of medications affecting metabolism or inflammation
Other illness
- Type 2 diabetes mellitus
- Uncontrolled thyroid disorders
- Patients with chronic inflammatory diseases
- Family history of hereditary or chromosomal diseases
Other
- Severe male factor (sperm concentration \<5M/mL)
- Contraindications to IVF or semaglutide treatment
- Use of glucocorticoids or immunosuppressants
- PGT-A
Who the study is looking for
- ≤ 38 years
- AMH \>= 1 ng/mL or AFC \>= 6
- Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
- Scheduled for IVF with freeze-all strategy
Age in the registry: 18 years to 38 years · Sex: Female · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Dexeus Mujer Reus Coordinator of this site? Confirm its status | Reus | Spain | Not yet recruiting |
| Dexeus Mujer Sabadell Coordinator of this site? Confirm its status | Sabadell | Spain | Not yet recruiting |
| Dexeus Mujer Sant Cugat Coordinator of this site? Confirm its status | Sant Cugat del Vallès | Spain | Not yet recruiting |
| Dexeus Mujer Tarragona Coordinator of this site? Confirm its status | Tarragona | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.